Landos Biopharma Completes $60 Million Series B Financing

- RTW Investments joins existing investor Perceptive Advisors in leading financing with a strong syndicate -

- Proceeds will support two global Phase 2 studies of lead product BT-11 for Ulcerative Colitis and Crohn’s disease, and advancement of additional pipeline candidates -

BLACKSBURG, VIRGINIA, August 13th, 2019 Landos Biopharma, Inc., a clinical-stage biopharmaceutical company focused on the discovery and development of first-in-class oral therapeutics for patients with autoimmune diseases, announced the successful completion of its $60 million Series B financing round. The financing was co-led by RTW Investments and Perceptive Advisors (Perceptive Xontogeny Venture Fund and Perceptive Life Sciences Fund).

“I am delighted to announce the closing of a $60 million Series B financing,” said Dr. Josep Bassaganya-Riera, Chairman of the Board, President, and CEO of Landos. “This financing is an important part of our strategy to advance lead product BT-11 into global Phase 2 clinical trials for ulcerative colitis and Crohn’s disease. There is an unmet clinical need for new therapies for complex diseases such as Inflammatory Bowel Disease. We are pleased that our investors share Landos’ mission of accelerating drug development and serving the unmet needs of millions of patients living with these widespread and debilitating conditions.”

This financing will support Landos’ Phase 2 global clinical trials for BT-11 in ulcerative colitis and Crohn’s disease. BT-11 is a first-in-class, oral, gut-restricted small molecule therapeutic with a unique mechanism of action that targets a novel pathway called Lanthionine Synthetase C-Like 2 (LANCL2). Results from Landos’ Phase 1 clinical trial (published in May 2019 in the IBD Journal) demonstrated that the compound was well-tolerated. Fecal calprotectin levels, which we believe is a predictive biomarker of response to treatment in IBD, were lower in all BT-11-treated groups when compared to placebo. We believe this activity provides initial biomarker evidence of response to treatment.

About Landos Biopharma

Landos Biopharma, Inc. is a clinical-stage biopharmaceutical company focused on the discovery and development of first-in-class oral therapeutics for patients with autoimmune diseases. Landos’ lead clinical asset, BT-11, is a first-in-class, oral therapeutic that acts locally in the gastrointestinal tract for treatment of inflammatory bowel disease (IBD). The company has completed Phase 1 clinical testing and has initiated Phase 2 clinical testing of BT-11 for inflammatory bowel disease in 2019. Landos also has a robust pipeline of new compounds for other autoimmune diseases, several of which Landos anticipates will advance to IND and Phase 1 clinical testing in 2020. Landos is headquartered in Blacksburg, VA. For more information, please visit or contact or follow us @Landosbio.


The NIMML tackles unsolved fundamental challenges in complex human diseases with unmet clinical needs. The NIMML combines advanced computational technologies such as computer modeling and artificial intelligence with pre-clinical and clinical experimentation to catalyze the translation of scientific discoveries into creative solutions to the most challenging problems in healthcare. NIMML is located in Blacksburg, VA.

Related Press Releases

Landos Biopharma Announces Publication of Results from First-in-Human Phase 1 Study of BT-11 in Healthy Volunteers

NIMML Helps Grow Virginia’s Biotech Ecosystem

Accelerating the Path to Cures: New Insights on the Application of Advanced Computational Approaches in Drug Development

Landos Biopharma Announces Final Safety Results from Phase 1 Study of BT-11 in Healthy Volunteers

Watch TEDx: Accelerated Path to Cures

NIMML Contact

Josep Bassaganya-Riera